METABOLISM AND CHIRALITY IN PSYCHOPHARMACOLOGY - INTRODUCTION

被引：6

作者：

BAKER, GB

COUTTS, RT

HOLT, A

机构：

来源：

BIOLOGICAL PSYCHIATRY | 1994年 / 36卷 / 04期

关键词：

D O I：

10.1016/0006-3223(94)90601-7

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

引用

页码：211 / 213

页数：3

共 32 条

[1] METABOLISM OF MONOAMINE-OXIDASE INHIBITORS [J].

BAKER, GB ;

COUTTS, RT .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1989, 13 (3-4) :395-403

[2] CLINICAL PHARMACOKINETICS OF CITALOPRAM AND OTHER SELECTIVE SEROTONERGIC REUPTAKE INHIBITORS (SSRI) [J].

BAUMANN, P .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1992, 6 :13-20

[3] QUANTIFICATION AND MECHANISM OF THE FLUOXETINE AND TRICYCLIC ANTIDEPRESSANT INTERACTION [J].

BERGSTROM, RF ;

PEYTON, AL ;

LEMBERGER, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (03) :239-248

[4] FLUOXETINE AND NORFLUOXETINE ARE POTENT INHIBITORS OF P450IID6 - THE SOURCE OF THE SPARTEINE DEBRISOQUINE OXIDATION POLYMORPHISM [J].

BROSEN, K ;

SKJELBO, E .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (01) :136-137

[5] RECENT DEVELOPMENTS IN HEPATIC DRUG OXIDATION - IMPLICATIONS FOR CLINICAL PHARMACOKINETICS [J].

BROSEN, K .

CLINICAL PHARMACOKINETICS, 1990, 18 (03) :220-239

[6]

CIRAULO DA, 1990, J CLIN PSYCHOPHARM, V10, P213

[7] FLUOXETINE DRUG-DRUG INTERACTIONS .1. ANTIDEPRESSANTS AND ANTIPSYCHOTICS [J].

CIRAULO, DA ;

SHADER, RI .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1990, 10 (01) :48-50

[8] MONOAMINE OXIDASE CATALYZED DEGRADATION OF PHENELZINE-1-14C AN IRREVERSIBLE INHIBITOR OF MONOAMINE OXIDASE .2. [J].

CLINESCHMIDT, BV ;

HORITA, A .

BIOCHEMICAL PHARMACOLOGY, 1969, 18 (05) :1021-+

[9] IMPLICATIONS OF CHIRALITY AND GEOMETRIC ISOMERISM IN SOME PSYCHOACTIVE-DRUGS AND THEIR METABOLITES [J].

COUTTS, RT ;

BAKER, GB .

CHIRALITY, 1989, 1 (02) :99-120

[10]

COUTTS RT, 1994, J PSYCHIATR NEUROSCI, V19, P30

← 1 2 3 4 →